MCL1 and breast carcinoma: For example, it has been illustrated that pro-inflammatory cytokine interleukin (IL)-6 potently stimulates JAK/STAT signaling in breast cancer cell lines, and it has also been shown that both IL-6 and JAK/STAT signaling can potentiate MCL1 transcription in multiple cancer subtypes [53–56].